Introduction {#S0001}
============

Nasopharyngeal carcinoma is one of the most common cancers in Southern China, and it is a disease with a distinct ethnic and geographic distribution \[[@CIT0001], [@CIT0002]\]. In contrast with other cancers, most nasopharyngeal carcinoma cases are undifferentiated, and the majority of newly diagnosed nasopharyngeal carcinoma patients have lymph node metastases. To date, it is known that Epstein-Barr virus (EBV) infection play a key role in pathogenesis of nasopharyngeal carcinoma. However, the molecular mechanisms involved in the progression and prognosis of nasopharyngeal carcinoma have not been fully elucidated.

Interleukin (IL)-35, a new immune-suppressing cytokine, is a heterodimeric cytokine composed of the p35 subunit of IL-12 and the EBI3 (Epstein-Barr virus-induced gene 3) subunit \[[@CIT0003]--[@CIT0006]\]. Interleukin 35 is expressed in non-stimulated murine regulatory T cells (T~reg~) and it is considered to be a characteristic marker for T~reg~ cells \[[@CIT0007]--[@CIT0010]\]. It is known that the anti-tumour activities of IL-12 have been extensively studied in a variety of human cancers \[[@CIT0011]\]. Because IL-35 shares the IL-12p35 and EBI3 subunits with IL-12, it might participate in the development or progression of cancers. Recently, immunohistochemical analysis EBI3 has up-regulated in acute myeloid leukaemia cells \[[@CIT0012]\] and Hodgkin lymphoma cells \[[@CIT0013], [@CIT0014]\]. Moreover, expressions of EBI3 and IL-12p35 are also enhanced in lung cancer \[[@CIT0015]\] and colon cancer \[[@CIT0016]\].

However, there has been no study concerning the correlation between IL-35 expression and clinicopathological parameters or prognosis in patients with nasopharyngeal carcinoma. In the present study, we determined the expression levels of the IL-35 in nasopharyngeal carcinoma cells, and investigated the possible role of IL-35 in the prognosis of nasopharyngeal carcinoma patients.

Material and methods {#S0002}
====================

Patients and tissue samples {#S20003}
---------------------------

Paraffin-embedded specimens from 80 patients with nasopharyngeal carcinoma were collected from the Department of Pathology, Xiangya hospital, from 2003 to 2004. The median follow-up period for the survivors was 50.8 (range, 9--93) months. Tumour stage was classified according to the pathology tumour-node-metastasis (pTNM) system (AJCC/UICC 2002). Histology was classified based on the World Health Organization (WHO) classification. The specimens were diagnosed pathologically by two pathologists. None of the patients had received radiotherapy or chemotherapy. Clinicopathological factors for these nasopharyngeal carcinoma patients are detailed in [Table 1](#T0001){ref-type="table"}. Patients whose cause of death remained unknown were excluded from our study. Informed consent on the collection of samples was obtained from each patient. The Institutional Research Medical Ethics Committee of Xiangya Hospital granted approval for this study.

###### 

Correlation of EBI3 and p35 expression with clinicopathological factors of nasopharyngeal carcinoma patients

  Variable                Cases   EBI3 expression Negative   *p*35 expression Positive   *p*     Negative   Positive   *p*
  ----------------------- ------- -------------------------- --------------------------- ------- ---------- ---------- -------
  Gender                                                                                                               
   Male                   41      11                         30                          0.787   18         23         0.502
   female                 39      7                          24                                  21         18         
  Age (years)                                                                                                          
   = 48                   35      10                         25                          0.808   19         16         0.499
   \< 48                  45      15                         30                                  20         25         
  Histological subtype                                                                                                 
   DNKC                   11      6                          5                           0.162   4          7          0.520
   UDC                    69      20                         49                                  35         34         
  Tumour stage                                                                                                         
   I + II                 22      13                         9                           0.003   17         5          0.002
   III + IV               58      13                         45                                  22         36         
  T classification                                                                                                     
   T1--T2                 33      7                          26                          0.092   18         15         0.496
   T3--T4                 47      19                         28                                  21         26         
  Lymph node metastasis                                                                                                
   N0--N1                 56      23                         33                          0.018   29         27         0.465
   N2--N3                 24      3                          21                                  10         14         

DNKC -- differentiated non-keratinising carcinoma; UDC -- undifferentiated carcinoma

Immunohistochemistry staining {#S20004}
-----------------------------

Paraffin-embedded sections were deparaffinised and rehydrated in graded concentrations of ethanol. The sections were submerged in citrate antigenic retrieval buffer and subjected to high pressure for antigenic retrieval. Then slides were incubated with EBI3 (1 : 200 dilution, sc-32868, Santa Cruz Biotechnology) and p35 (1 : 150 dilution, sc-7925, Santa Cruz Biotechnology) at 4°C overnight. Labelling was detected by adding biotinylated secondary antibodies (Maxim-Bio, Fuzhou, China), avidin--biotin complex (Maxim-Bio), and stained with DAB (Maxim-Bio). Finally, sections were counterstained with haematoxylin and viewed under a light microscope. A negative control was obtained by replacing the primary antibody with a normal murine IgG, and human colorectal cancer tissue was used as positive control. Expressions of EBI3 and p35 were scored according to the positive percentage and staining intensity of the stained cancer cells. The percentage positivity was scored as 0 (0--25%), 1 (26--50%), 2 (51--75%), and 3 (\> 75%). The staining intensity was scored as 0 (no staining), 1 (weakly stained), 2 (moderately stained), and 3 (strongly stained). If the product of multiplication between staining intensity and the percentage of positive cells was ≥ 2, it was taken as immunoreaction positive (+).

Statistical analysis {#S20005}
--------------------

All statistical analyses were carried out using SPSS13.0 software. Fisher\'s exact test was used to analyse the correlation between the clinicopathological characteristics and EBI3, p35 expression. Survival curves were obtained with the Kaplan-Meier method. Multivariate analysis was performed using Cox proportional hazards regression. *p* \< 0.05 denotes the presence of a statistically significant difference.

Results {#S0006}
=======

EBI3 and p35 expression in nasopharyngeal carcinoma cells {#S20007}
---------------------------------------------------------

To explore the expression levels of EBI3 and p35 in nasopharyngeal carcinoma cells, immunohistochemical assay was used in 80 cases. Expression levels of EBI3 and p35 were increased in these series of nasopharyngeal carcinoma samples, as shown in [Figure 1](#F0001){ref-type="fig"}. In our experimental group, EBI3 expression was found in 54 cases (67.5%, 54/80). In addition, p35 immunoreactivity was present in 41 cases (51.3%, 41/80). Compared with no staining in the normal nasopharyngeal mucosa, EBI3 and p35 were over-expressed in the cytoplasm of the nasopharyngeal carcinoma cells ([Fig. 1](#F0001){ref-type="fig"}).

![EBI3 and p35 expression in nasopharyngeal carcinoma samples by immunohistochemistry. **A, E**) No staining of EBI3 and p35 in non-tumoural nasopharyngeal mucosa (×200). **B, C, D**) Positive expression of EBI3 in the cytoplasmic of nasopharyngeal carcinoma cells (×200). **F, G, H**) Positive expression of p35 in the cytoplasmic of nasopharyngeal carcinoma cells (×200)](WO-19-23365-g001){#F0001}

Correlation of EBI3 and p35 expression with clinicopathological factors of nasopharyngeal carcinoma patients {#S20008}
------------------------------------------------------------------------------------------------------------

To further investigate the clinical significance of IL-35 in nasopharyngeal carcinoma specimens, the correlation between IL-35 expression and clinicopathological factors was explored. As summarised in [Table 1](#T0001){ref-type="table"}, EBI3 expression was significantly associated with tumour stage (*p* = 0.003) and lymph node metastasis (*p* = 0.018). There were no significant correlations between EBI3 staining and sex, age, histological subtype, or T classification (*p* \> 0.05). Similarly, there was a positive correlation between p35 expression and tumour stage (*p* = 0.002). These results demonstrated IL-35 participated in advancement of nasopharyngeal carcinoma.

The influence of EBI3 and p35 expressions on overall survival in patients with nasopharyngeal carcinoma {#S20009}
-------------------------------------------------------------------------------------------------------

To assess the prognostic role of IL-35 in nasopharyngeal carcinoma patients, overall survival rates were estimated by Kaplan-Meier survival curves. As shown in [Figure 2](#F0002){ref-type="fig"}, patients with positive expression of EBI3 had a significantly shorter survival time than those cases with no staining of EBI3. Multivariate analyses of factors related to patient prognosis are shown in [Table 2](#T0002){ref-type="table"}. Our results indicated that EBI3 was independently associated with patient outcome (hazard ratio 3.265, 95% CI 1.175--7.335, *p* = 0.042). Additionally, tumour stage (hazard ratio 3.137, 95% CI 1.306--8.423, *p* = 0.031) and lymph node metastasis (hazard ratio 0.145, 95% CI 0.049--0.798, *p* = 0.025) were significantly correlated with patient survival. The prognostic impact of p35 was also analysed. Interestingly, although patients with p35 positive expression were associated with a worse overall survival (*p* \< 0.05), multivariate analyses suggested p35 was not an independent prognostic predictor of nasopharyngeal carcinoma patients (hazard ratio 2.836; 95% CI 0.893--5.376, *p* = 0.078). In all clinicopathological parameters, lymph node metastasis was the most independent factor for prognosis.

![Kaplan-Meier survival analysis according to EBI3 or p35 expression in nasopharyngeal carcinoma patients. **A**) The nasopharyngeal carcinoma patients with positive EBI3 expression had unfavourable prognosis compared to those with negative ones. **B**) The nasopharyngeal carcinoma patients with positive p35 expression had shorter survival times than those with negative expression](WO-19-23365-g002){#F0002}

###### 

Multivariate analysis of overall survival in nasopharyngeal carcinoma patients

  Factor                  Hazard ratio   95% confidence interval   *p* value
  ----------------------- -------------- ------------------------- -----------
  Gender                  1.482          0.613--3.435              0.236
  Age \[year\]            1.142          0.922--1.059              0.547
  Histological subtype    1.054          0.441--3.286              0.973
  Tumour stage            3.137          1.306--8.423              0.031
  T classification        0.772          0.296--2.784              0.794
  Lymph node metastasis   0.145          0.049--0.798              0.025
  EBI3 expression         3.265          1.175--7.335              0.042
  p35 expression          2.836          0.893--5.376              0.078

Discussion {#S0010}
==========

Interleukin 35, a novel member of the IL family, had an immunosuppressive function of regulatory T cells. As an anti-inflammatory cytokine, previous studies reported that IL-35 plays a vital role in the regulation of autoimmune diseases \[[@CIT0017]--[@CIT0019]\]. Recently, the effects of IL-35 involved in the development and progression of cancer has attracted more attention. Taking into account immunosuppression of IL-35, it is not hard to see that it can contribute to the advancement of cancer. However, Long *et al*. \[[@CIT0011]\] revealed that overexpression of IL-35 increased cell apoptosis and suppressed cell growth in human cancer cells. These contradictory findings demonstrate that the exact role of IL-35 on cancer, especially in nasopharyngeal carcinoma, needs further investigation.

To the best of our knowledge, this is the first study to investigate the role of IL-35 in the outcome of the nasopharyngeal carcinoma patients. In the present study, we have observed EBI3 and p35 staining localised in the cytoplasm of nasopharyngeal carcinoma cells. Moreover, as described in other cancers, both EBI3 and p35 were highly expressed in cancer cells compared with non-tumoural nasopharyngeal epithelium, indicating that they might be involved in the pathogenesis of nasopharyngeal carcinoma. Immunohistochemistry assay demonstrated that EBI3 and p35 staining were all significantly associated with advancement of tumour stage. Our results were consistent with the report from Zeng *et al*. \[[@CIT0016]\], which stated that in colorectal cancer, higher levels of p35 and EBI3 expressions were noted in stage IV tumour samples. Furthermore, EBI3 expression was also correlated with lymph node metastasis. These findings suggest that IL-35 is vital for progression of nasopharyngeal carcinoma. To better elucidate the clinical significance of IL-35 in nasopharyngeal carcinoma, we are further studying the impact of IL-35 on the prognosis of patients with nasopharyngeal carcinoma.

A significant reduction in serum IL-35 was noted in patients after surgical resection, and IL-35 promoted progression of colorectal cancer and influenced prognosis of colorectal cancer patients. Ito *et al*. reported that a high level of EBI3 expression was associated with a poor prognosis of lung cancer, and that it is an independent prognostic factor. In this study we also observed that negative expression of EBI3 was significantly associated with a better prognosis and prolonged overall survival. Interestingly, although p35 positive expression was associated with a worse survival, multivariate analyses suggested p35 was not an independent prognostic predictor.

In summary, in the present study, we evaluated the expression pattern of IL-35 in nasopharyngeal carcinoma cells and its association with clinicopathological factors. Our data suggest that IL-35 is involved in the progression of nasopharyngeal carcinoma. Moreover, expressions of EBI3 and p35 are correlated with unfavourable prognosis. Therefore, IL-35 may be a new biomarker for the prognosis of nasopharyngeal carcinoma patients.
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